Observatory of adults with Ph+ ALL receiving BCR-ABL1 inhibitors with chemotherapy, steroids, or monoclonal antibodies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study enrolling adults with Ph+ ALL who are treated with a combination of BCR-ABL1 inhibitors and chemotherapy and/or corticosteroids and/or monoclonal antibodies. Data will be collected to describe treatment patterns, real-world outcomes, and safety signals in routine clinical care. No experimental interventions are required beyond standard treatment, and no randomization is involved. Participation is limited to patients who consent to data collection and are treated at participating centers. The study aims to provide insights into how these combination regimens perform outside of controlled trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female patients ≥ 18 years
2. Philadelphia chromosome or BCR::ABL1 positive acute lymphoblastic leukaemia
3. Treatment with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticotherapy and/or a monoclonal antibody

Exclusion Criteria:

1. Patients deceded and having previously refused data collection
2. Not included in a prospective clinical trial

Where it's running

• CHU Bordeaux
  Bordeaux, France Recruiting
• CHU clermont ferrand
  Clermont-Ferrand, France Recruiting
• Centre Hospitalier sud francilien
  Corbeil-Essonnes, France Recruiting
• CH Versailles
  Le Chesnay, France Recruiting
• CH Le Mans
  Le Mans, France Recruiting
• Hopital necker
  Paris, France Recruiting

Study contacts

• Study coordinator: Sandrine Roux
• Email: sroux@ght78sud.fr
• Phone: +33139239777

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• CD19-targeted CAR-T cells that make p40 for relapsed or refractory CD19-positive blood cancers

  This trial will try a patient's own CD19-directed CAR-T cells engineered to produce p40 to see if they work better and last longer in adults with relapsed or refractory CD19-positive blood cancers.

  Recruiting Phase 1/2 Shenzhen University General Hospital · Shenzhen, Other (Non U.s.) · NCT07584889

• TSLPR-CART therapy for CRLF2-R/TSLPR–expressing B-ALL in adults

  This study tests a CAR T-cell treatment called TSLPR-CART in adults whose B-ALL cells overexpress TSLPR and have not responded to standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07572136

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.